Walid Macaron, MD MSc
@WNMacaron
Followers
775
Following
621
Media
15
Statuses
154
PGY-3 @BCM_InternalMed • Former Researcher @MDAndersonNews Leukemia Dpt • MD, MSc in Genetics and Molecular Biology @USJLiban • #GGMU • 🇱🇧
Houston, TX
Joined June 2021
An incredible experience presenting our work at #ASH24! .Truly grateful for the guidance and support from the best mentor @NicholasShortMD.
2
0
25
RT @FadiHaddad_MD: Survival of adult #ALL is significantly better 👍. ‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontlin….
0
8
0
RT @DrHKantarjian: Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD metho….
0
39
0
RT @PeterHotez: Our @TXMedCenter before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Hou….
0
169
0
RT @thenasheffect: ‼️Only data so far of ICI in pts with cardiac Mets. Work led by @AminNassarMD @sarahaboualaiwi @TalalZarif1 out in @jitc….
jitc.bmj.com
Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.Methods This is an...
0
11
0
RT @OncoAlert: Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter intern….
0
16
0
RT @DrChoueiri: Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patie….
jitc.bmj.com
Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.Methods This is an...
0
21
0
RT @ALL_Hub_: CONGRESS #ASH24 | PRESENTATION.@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and posit….
0
7
0
RT @JACCJournals: Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was ob….
0
7
0
RT @PennThalheimer: 🫀Don't miss this original research from a great team in @JACCJournals! 📰 @AminNassarMD @DrChoue….
0
13
0
RT @MDAndersonNews: Adding gilteritinib to azacitidine and venetoclax shows improved outcomes in patients with FLT3-mutated acute myeloid l….
ascopubs.org
PURPOSEAzacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, FLT3 mutations are a common mechanism of resistance...
0
10
0
RT @NicholasShortMD: Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at @JCO_ASCO.In frontline FLT3mut AML, CR 90% (vs. 30….
ascopubs.org
PURPOSEAzacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, FLT3 mutations are a common mechanism of resistance...
0
23
0
RT @DrHKantarjian: Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML: CR/CRi 96% and 18-month OS 72%. A new standar….
0
55
0
RT @AminNassarMD: What a pleasure working on this multi-center effort with dear friends/colleagues under the mentorship of @DrChoueiri @the….
0
8
0
RT @MDAndersonNews: We are proud to celebrate our Dr. Hagop Kantarjian receiving the prestigious David A. Karnofsky Memorial Award from @AS….
0
26
0
RT @jayastuMD: The lifestory of Prof @DrHKantarjian: an inspiring showcase of his efforts that has changed the face of leukemia therapy ove….
0
9
0
RT @NicholasShortMD: If you will be at #ASCO23 please join @DrHKantarjian, Dr. Elias Jabbour and me on June 3rd at 7PM at the Radisson Blue….
0
5
0
RT @FadiHaddad_MD: Just out 📢 all you need to know about #MRD in Ph-positive ALL: high-sensitivity NGS-based assay for IG/TCR vs. standard….
0
1
0
0
0
0
✔️ NGS is prognostic in Ph+ ALL and may be superior in discriminating risk of relapse. ✔️ NGS identifies patients with low-level detectable BCR::ABL1 who are unlikely to relapse nor to benefit from therapeutic intervention. #ALLsm .@NicholasShortMD @DrHKantarjian.
1
0
2